Price Data Unavailable
Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.
Next stock NESR
Previous stock NEPT
WallstreetBets Trending Stocks (24h)